You are in: eMedicine Specialties > Emergency Medicine > ENVIRONMENTAL Lionfish and StonefishArticle Last Updated: Jun 8, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Scott A Gallagher, MD, FACEP, Chairman, Department of Emergency Medicine, Aspen Valley Hospital; Senior Clinical Instructor, Department of Surgery, School of Medicine, University of Colorado Health Sciences Center Scott A Gallagher is a member of the following medical societies: American College of Emergency Physicians and Wilderness Medical Society Editors: Robert Norris, MD, Chief, Associate Professor, Department of Surgery, Division of Emergency Medicine, Stanford University Medical Center; John T VanDeVoort, PharmD, ABAT, Director of Pharmacy, Sacred Heart Hospital; James S Walker, DO, Program Coordinator, Associate Professor, Department of Emergency Medicine, University of Oklahoma Health Sciences Center; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School Author and Editor Disclosure Synonyms and related keywords: lionfish envenomations, stonefish envenomations, scorpionfish envenomations, Scorpaenidae, Pterois species, Scorpaena species, Synanceia species, Scorpaenidae envenomations INTRODUCTIONBackgroundThe family Scorpaenidae represents a large array of fish characterized by the ability to envenomate with various types of specialized spines. This group of fish is responsible for the second most common piscine envenomation, after stingrays. Unfortunately, this family of fish has a confusing variety of common names, which tends to hinder accurate field identification, classification, and understanding of their envenomations. It is helpful to consider the Scorpaenidae family as 3 distinct groups, based upon their venom organ structure and toxicity. These 3 groups and their representative genera include the following:
Injury and envenomation are reported in the natural environment (eg, accidental exposure to waders, divers, fishermen), as well as in the home setting (eg, handling by unwary marine aquarists). PathophysiologyCommon to the family Scorpaenidae are 12-13 dorsal spines, 2 pelvic spines, and 3 anal spines. Each spine is associated with a pair of venom glands. A loose integumentary sheath covers each spine. The sheath is pushed down the spine during envenomation, causing compression of the venom glands located at the base of the spines. Venom then travels from the glands through anterolateral depressions in the spines and into the wound, in a manner analogous to that of a stingray envenomation. The pectoral spines, while often ornate and plumelike, are innocuous. The venom toxicity is due to antigenic, heat-labile proteins of high molecular weight. Treatment is based on the proposed heat-labile characteristics of these proteins. FrequencyUnited StatesThe true number of Scorpaenidae envenomations is unknown. However, there are more than 100 reported cases of captive lionfish (genus Pterois) envenomations in the medical literature, nearly all of which occur on the hands of unwary marine aquarists. Reports from coastal locales commonly involve fisherman, divers, and other water enthusiasts who inadvertently may step on or carelessly handle members of the Scorpaenidae family. InternationalThis large family is widespread throughout the tropical, subtropical, and temperate regions. Some species are even found in polar regions. No accurate estimates regarding the international frequency of Scorpaenidae envenomations are available; however, they are not uncommon. While the tropical seas contain the majority of species, the temperate waters of the Indo-Pacific, India, South Africa, Australia, Philippines, China, Japan, and the United States are home to many venomous Scorpaenidae. Mortality/MorbidityThe severity of Scorpaenidae envenomations is progressively worse from Pterois to Scorpaena to Synanceia species. Pterois (eg, lionfish, zebrafish, turkey fish, butterfly cod): In one series of 101 described cases of captive lionfish (genus Pterois) envenomations in the United States, 92% of patients experienced local pain, 60% experienced edema, and 13% experienced systemic symptoms. There were no fatalities. Wounds were graded with the use of a grading system, and 95% of the wounds were found to be grade I (erythema), 4% were found to be grade II (vesicle formation), and 1% were found to be grade III (tissue necrosis). Pain was relieved with hot-water immersion therapy in 97% of the patients, and 0% of the patients required antivenom administration. One patient required intravenous antibiotics, one hypotensive patient responded well to intravenous fluids, and 13% of patients had variable, less severe, systemic symptoms. Judging from this and other reports in the United States, the vast majority of lionfish stings appear to result in uncomplicated wounds with severe local pain that is responsive to immersion therapy. While reports of fatalities exist, detailed documentation is sparse and deaths must be very rare. Scorpaena (eg, scorpionfish, bullrout, sculpin) and Synanceia (eg, stonefish, warty-ghoul, "nofu"): Wound severity and systemic symptoms are generally accepted to be greater in Scorpaena and Synanceia envenomations as compared to Pterois envenomations. Of some controversy is the purported lethality of these envenomations. Fenner and Williamson note the absence of any well-documented Australian fatalities or life-threatening symptoms and go on to cite only 3 specific references in the literature of death attributable to envenomation by stonefish. One of these cases (Mozambique, 1957) was postulated to represent direct intravascular deposition of venom or, perhaps, anaphylaxis, as the victim's foot showed no local reaction. Other reports describe deaths occurring days or months following envenomation, raising suspicion of secondary complications (eg, wound infection, tetanus). Whatever the actual mortality rate is following a stonefish envenomation, the number of confirmed human deaths is much fewer than commonly believed. Nonetheless, severe and incapacitating local and systemic effects are well described. CLINICALHistory
PhysicalThe severity of envenomation depends upon multiple factors including the offending species, the number of stings, and the age and underlying health of the victim. Scorpaenidae stings are progressively more severe from Pterois (lionfish) to Scorpaena (scorpionfish) to Synanceia (stonefish).
DIFFERENTIALSAnaphylaxis Decompression Sickness Dysbarism Echinoderm Envenomations Serum Sickness Snake Envenomations, Sea Stingray Envenomations
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Bupivacaine (Marcaine, Sensorcaine) |
|---|---|
| Description | In general, any of the commonly used local anesthetics suffices; however, bupivacaine provides superior duration of anesthesia for irrigation, wound exploration, and debridement as compared to shorter-acting anesthetics. Bupivacaine increases the patient's electrical excitation threshold, which slows nerve impulse propagation and reduces the action potential; therefore, it prevents the generation and conduction of nerve impulses. |
| Adult Dose | 10-20 mL of 0.25-0.5% intralesionally; not to exceed 3-4 mg/kg |
| Pediatric Dose | Not established; 1.25 mg/kg/dose intralesionally suggested |
| Contraindications | Documented hypersensitivity; septicemia, spinal deformities, severe hypertension, and existing neurologic disease |
| Interactions | May enhance effects of CNS depressants; coadministration may increase toxicity of MAOIs, TCAs, beta-blockers, vasopressors, and phenothiazines |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Test a dose and monitor for CNS toxicity, cardiovascular toxicity, and signs of unintended intrathecal administration; caution with inflammation or sepsis in region of proposed injection; monitor patient's state of consciousness after each injection; caution in hypertension, cerebral vascular insufficiency, peripheral vascular disease or heart block, and arteriosclerotic heart disease |
Used for adjunctive pain control when immersion therapy and local/regional anesthesia are not sufficient.
| Drug Name | Morphine sulfate (MS Contin, Astramorph, Oramorph) |
|---|---|
| Description | DOC for narcotic analgesia due to its reliable and predictable effects, safety profiles, and ease of reversibility with naloxone. Morphine sulfate administered IV may be dosed in a number of ways and is commonly titrated until the desired effect is obtained. The analgesic route, whether oral or parenteral, is a matter of choice. With appropriate local or regional anesthesia, this medication may not be necessary. |
| Adult Dose | 0.1 mg/kg IV/IM/SC initially followed by a maintenance dose of 5-20 mg/70 kg IV/IM/SC q4h Relatively hypovolemic patients: Start with 2 mg IV/IM/SC and reassess hemodynamic effects of the dose Alternatively, 0.1 mg/kg IV/IM/SC |
| Pediatric Dose | Neonates: 0.05-0.2 mg/kg/dose IV prn Children: 0.1-0.2 mg/kg/dose IV q2-4h prn; not to exceed 15 mg/dose IV |
| Contraindications | Documented hypersensitivity; hypotension; potentially compromised airway where establishing rapid airway control would be difficult |
| Interactions | Phenothiazines may antagonize analgesic effects of opiate agonists; tricyclic antidepressants, MAOIs, and other CNS depressants may potentiate adverse effects of morphine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Avoid in hypotension, respiratory depression, nausea, emesis, constipation, and urinary retention; caution in atrial flutter and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate |
Used for outpatient treatment of early or minor wound infections and as prophylaxis for high-risk wounds (eg, deep puncture wounds, grossly contaminated wounds, persons who are chronically ill or immunocompromised). Trimethoprim/sulfamethoxazole, ciprofloxacin, tetracycline, and doxycycline are referenced as the initial oral antibiotics of choice. Others mentioned include cephalexin, amoxicillin, and amoxicillin clavulanate.
Parenteral antibiotics are indicated for the treatment of serious wound infections (eg, extensive cellulitis, myositis, gas gangrene) or sepsis following injuries sustained in the marine environment. Vibrio wound infection approaches 50% mortality (usually patients with chronic liver disease), and serious Aeromonas infection may mimic clostridial gas gangrene.
| Drug Name | Trimethoprim/sulfamethoxazole (Bactrim, Septra) |
|---|---|
| Description | Inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic, acid-inhibiting, folic acid synthesis. This results in the inhibition of bacterial growth. The antibacterial activity of TMP-SMZ includes the common urinary tract pathogens except Pseudomonas aeruginosa. |
| Adult Dose | 160 mg TMP/800 mg SMZ IV q12h for 10-14 d |
| Pediatric Dose | <2 months: Do not administer >2 months: 15-20 mg/kg/d IV, based on TMP, tid/qid for 14 d |
| Contraindications | Documented hypersensitivity; megaloblastic anemia due to folate deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases incidence of thrombocytopenia purpura in elderly; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Discontinue drug at first appearance of skin rash or any sign of adverse reaction; frequently obtain CBCs; if a significant reduction in the count of any formed blood element is noted, discontinue therapy; goiter production, diuresis, and hypoglycemia may occur; high IV doses or prolonged infusions may cause bone marrow depression manifested as thrombocytopenia, leukopenia, or megaloblastic anemia; caution in patients with possible folate deficiency, such as chronic alcoholics, the elderly, and those receiving anticonvulsant therapy or with malabsorption syndrome Hemolysis may occur in G-6-PD deficiency; if signs of bone marrow depression occur, give leucovorin as needed to restore normal hematopoiesis (PO leucovorin, 5-15 mg/d, has been recommended); because of their unique immune dysfunction, patients with AIDS may not tolerate or respond to TMP-SMZ; caution in renal or hepatic impairment; administer adequate fluid intake to prevent crystalluria and stone formation; perform urinalyses and renal function tests during therapy |
| Drug Name | Ciprofloxacin (Cipro) |
|---|---|
| Description | Bactericidal antibiotic that inhibits bacterial DNA synthesis and, consequently, growth by inhibiting DNA-gyrase in susceptible organisms. Indicated for pseudomonal infections and those that are due to multidrug resistant gram-negative organisms. Duration of treatment depends upon severity of infection. Generally, treatment should be continued for at least 2 d after the signs and symptoms of infection have disappeared. The usual treatment duration is 7-14 d. No controlled studies exist regarding efficacy of therapy. Several references suggest both a tetracycline and either an extended-spectrum cephalosporin (eg, ceftazidime) or an aminoglycoside. |
| Adult Dose | 250-500 mg PO bid for 7-14 d |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; ciprofloxacin reduces therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Tetracycline (Sumycin) |
|---|---|
| Description | Treats susceptible bacterial infections of both gram-positive and gram-negative organisms as well as infections caused by Mycoplasma, Chlamydia, and Rickettsia species. Inhibits bacterial protein synthesis by binding with the 30S, and possibly the 50S, ribosomal subunit(s) of susceptible bacteria. |
| Adult Dose | 250-500 mg PO q6h Mild-to-moderate infections: 500 mg PO bid or 250 mg PO qid for 7-14 d Severe infections: 500 mg PO qid for 7-14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 10-20 mg/lb (25-50 mg/kg) PO qid |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Doxycycline (Doryx, Bio-Tab) |
|---|---|
| Description | Inhibits protein synthesis and, thus, bacterial growth by binding with the 30S, and possibly the 50S, ribosomal subunits of susceptible bacteria |
| Adult Dose | Acute infection: 200 mg PO/IV immediately and 100 mg hs followed by 100 mg bid for 3 d Alternatively, administer 300 mg PO/IV immediately followed by 300 mg in 1 h, or 100 mg PO/IV bid for 7 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 2-5 mg/kg/d PO/IV in 1-2 divided doses; not to exceed 200 mg/d |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Ceftazidime (Fortaz, Ceptaz) |
|---|---|
| Description | Third-generation cephalosporin that has broad gram-negative spectrum, lower efficacy against gram-positive organisms, and higher efficacy against resistant organisms. By binding to one or more of the penicillin-binding proteins, it arrests bacterial cell wall synthesis and inhibits bacterial growth |
| Adult Dose | 500 mg to 2 g IV/IM q8-12h |
| Pediatric Dose | 1-4 weeks: 30 mg/kg q12h IV/IM 1 month to 12 years: 30-50 mg/kg/dose IV/IM q8h; not to exceed 6 g/d >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Nephrotoxicity may increase with aminoglycosides, furosemide, and ethacrynic acid; probenecid may increase ceftazidime levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment |
| Drug Name | Ampicillin (Marcillin, Omnipen) |
|---|---|
| Description | Interferes with bacterial cell wall synthesis during active multiplication, causing bactericidal activity against susceptible organisms. |
| Adult Dose | 2 g IV/IM 30 min prior to procedure |
| Pediatric Dose | 50 mg/kg IV/IM 30 min prior to procedure |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
Premedication is recommended by several sources because of the risks of allergic reaction and serum sickness with antivenom. In the presence of clear and severe clinical signs of stonefish envenomation, antivenom should not be withheld solely because of such considerations. The choice of specific premedication drugs is controversial but generally should include an antihistamine and epinephrine (when not contraindicated).
| Drug Name | Epinephrine (EpiPen, Adrenalin) |
|---|---|
| Description | DOC for the treatment of anaphylactoid reactions and should be considered as pretreatment prior to giving antivenom. |
| Adult Dose | 0.01 mL/kg IM/SC of a 1:1,000 solution initially to a maximum of 0.5 mL of the 1:1,000 solution (0.5 mg) |
| Pediatric Dose | 0.1 mcg/kg/min SC IM/SC q15 min for 2 doses, then q4h with increments of 0.1 mcg/kg/min prn; not to exceed 1.5 mcg/kg/min |
| Contraindications | Documented hypersensitivity; cardiac arrhythmias or angle-closure glaucoma; local anesthesia in areas such as fingers or toes because vasoconstriction may produce sloughing of tissue; labor (may delay second stage of labor) |
| Interactions | Epinephrine may potentiate hypertension when combined with MAOIs, tricyclic antidepressants, and vasopressors; increases toxicity of beta- and alpha-blocking agents and of halogenated inhalational anesthetics |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in elderly patients, prostatic hypertrophy, hypertension, cardiovascular disease, diabetes mellitus, hyperthyroidism, and cerebrovascular insufficiency; rapid IV infusions may cause death from cerebrovascular hemorrhage or cardiac arrhythmias |
Another antivenom premedication choice to minimize adverse effects.
| Drug Name | Diphenhydramine (Benadryl) |
|---|---|
| Description | Used for the symptomatic relief of allergic symptoms caused by histamine release in response to allergens. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 400 mg/d If necessary, 10-50 mg IV/IM q6-8h; not to exceed 400 mg/d |
| Pediatric Dose | 12.5-25 mg PO/IV/IM, tid/qid, or 5 mg/kg/d, or 150 mg/m2/d divided tid/qid; not to exceed 300 mg/d |
| Contraindications | Documented hypersensitivity; MAOIs |
| Interactions | Potentiates effect of CNS depressants; due to alcohol content, do not give syrup dosage form to patients taking medications that can cause disulfiramlike reactions |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, or urinary tract obstruction; xerostomia may occur |
May be useful in preventing or treating serum sickness associated with antivenom use.
| Drug Name | Hydrocortisone (Hydrocortone Phosphate, Solu-Cortef) |
|---|---|
| Description | Prophylactic corticosteroids may prevent later serum sickness, although to date, there have been no cases reported in the literature of delayed serum sickness following any administration of marine antivenom. Hydrocortisone decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. |
| Adult Dose | Loading dose of 250 mg IV up to 1 g, followed by 7 mg/kg/d IV/PO for 1-2 d |
| Pediatric Dose | Children: Not established Adolescents: Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, fungal, or tubercular skin infections |
| Interactions | Corticosteroid clearance may decrease with estrogens; may increase digitalis toxicity secondary to hypokalemia |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in hyperthyroidism, osteoporosis, peptic ulcer, cirrhosis, nonspecific ulcerative colitis, diabetes, and myasthenia gravis |
| Drug Name | Methylprednisolone (Solu-Medrol, Depo-Medrol) |
|---|---|
| Description | Useful to treat inflammatory and allergic reactions. By reversing increased capillary permeability and suppressing PMN activity, may decrease inflammation. A multitude of corticosteroid preparations are available. Methylprednisolone is widely available in the ED due to its other uses (eg, acute asthma, spinal cord injury) and is supplied in both parenteral and oral formulations. It is therefore discussed here as a typical drug of this class. |
| Adult Dose | 2-60 mg PO qd 40-250 mg IV q6h 40-250 mg IM q6h |
| Pediatric Dose | 1-2 mg/kg PO qd 1-2 mg/kg IV q6h 1-2 mg/kg IM q6h |
| Contraindications | Documented hypersensitivity; some evidence exists for fetal harm from corticosteroids, so both benefits and risks should be considered for use during pregnancy; immunosuppressed patients receiving corticosteroids are at risk for dissemination, activation, or certain infections, and this should be considered when prescribing for these patients |
| Interactions | NSAIDs may cause ulcers when taken concurrently; anticholinesterases may increase weakness in patients with myasthenia gravis when taken concurrently with steroids; risk exists of possible viral dissemination with live virus vaccines |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Short-term use of corticosteroids, even in large doses, has minimal harmful effects; chronic usage has multiple adverse effects Possible complications include hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, or infections |
Tetanus results from elaboration of an exotoxin from Clostridium tetani. A booster injection in previously immunized individuals is recommended to prevent this potentially lethal syndrome. Patients who may not have been immunized against C tetani products (eg, immigrants, the elderly) should receive tetanus immune globulin (Hyper-Tet)
| Drug Name | Diphtheria-tetanus toxoid (dT) |
|---|---|
| Description | Used for the passive immunization of any person with a wound that might be contaminated with tetanus spores. |
| Adult Dose | Prophylaxis: 250-500 U IM in opposite extremity to tetanus toxoid lesion Clinical tetanus: 3000-10,000 U IM |
| Pediatric Dose | Prophylaxis: 250 U IM in opposite extremity as tetanus toxoid lesion Clinical tetanus: Administer as in adults |
| Contraindications | Documented hypersensitivity; history of any type of neurological symptoms or signs following administration of this product; FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis |
| Interactions | Patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization due to poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol since it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude concurrent use) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use to treat actual tetanus infections, or for immediate prophylaxis of unimmunized individuals (use instead tetanus antitoxin, preferably human tetanus immune globulin); diminished antibody response to active immunization may be seen in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy is discontinued; routine immunization of persons with symptomatic and asymptomatic HIV infection is recommended; persons with isolated IgA deficiency have potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA Do not perform skin testing, since the intradermal injection of concentrated gamma globulin may cause a localized area of inflammation that can be misinterpreted as a positive allergic reaction when it is actually a localized chemical tissue irritation; true allergic responses to human gamma globulin given in the prescribed IM manner are extremely rare; do not admix with other medications, usually incompatible |
Used in previously unvaccinated individuals to provide passive immunity to tetanus when individuals become exposed.
| Drug Name | Tetanus immune globulin (Hyper-Tet) |
|---|---|
| Description | Used for passive immunization of any person with a wound that might be contaminated with tetanus spores. |
| Adult Dose | Prophylaxis: 250-500 U IM in opposite extremity to tetanus toxoid lesion Clinical tetanus: 3000-10,000 U IM |
| Pediatric Dose | Prophylaxis: 250 U IM in opposite extremity to tetanus toxoid Clinical tetanus: 3000-10,000 U IM |
| Contraindications | Since antibodies in globulin preparation may interfere with immune response to vaccination, do not administer within 3 mo of live virus immune globulin administration; may be necessary to revaccinate persons who received immune globulin shortly after live virus vaccination |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Persons with isolated immunoglobulin A (IgA) deficiency have potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA; do not perform skin testing since intradermal injection of concentrated gamma globulin may cause localized area of inflammation and can be misinterpreted, causing the medication to be withheld from a patient not allergic to this material; true allergic responses to human gamma globulin given in prescribed IM manner are extremely rare; do not admix with other medications since usually incompatible |
Has clearly established efficacy for analgesia and diminution of tissue damage following envenomation by Synanceia species and may be considered for serious or nonresponding stings of other members of the Scorpaenidae family. It generally is not indicated for Pterois envenomations.
Unlike box jellyfish (Chironex) envenomations, which often require immediate antivenom administration, the clinical situation after stonefish envenomation may allow for a skin test for sensitivity to horse serum to be performed. The purpose of skin testing is to allow for adequate preparation of pretreatment, if needed, not to decide whether to administer the antivenom. This decision is based upon the clinical condition of the patient before skin testing. In addition to pretreatment, a positive skin test may warrant greater antivenom dilution in order to be safely administered.
| Drug Name | Stonefish antivenom (Purified Equine) |
|---|---|
| Description | All Australian marine antivenoms were previously made by and available from the Commonwealth Serum Laboratories, 45 Poplar Road, Parkville, Vic 3052, Australia. However, Australian venom research is now centered at the Australian Venom Research Unit, Department of Pharmacology, University of Melbourne, Parkville, Vic 3052, Australia (tel: 61-3-934447753 / fax: 61-3-93482048). Stonefish antivenom is no longer available at the Health Services Department, Sea World, San Diego, CA; Sharp Cabrillo Hospital, San Diego, CA; Steinhart Aquarium, San Francisco, CA; or at Sea World, Aurora, OH. Regional poison control centers may be the most helpful sources of information. Known severe sensitivity to horse serum may prompt consideration of supportive therapy without antivenom administration. |
| Adult Dose | 1 ampule (2000 U) IV for every 1-2 punctures, up to 3 ampules for > 4 punctures Australia's Commonwealth Serum Laboratories (CSL) stonefish antivenom is recommended only for prediluted IM use (This route may not be ideal in serious envenomations because of erratic absorption) Slow IV administration requires dilution in 50-100 cc of normal saline run through at least 20 min Premedication is recommended |
| Pediatric Dose | Administer as in adults; dosage is not reduced for small patients or children |
| Contraindications | If history is positive (allergic reaction upon exposure to horses or prior injections of horse serum) and skin test is positive, administration may be dangerous, especially if positive sensitivity test is accompanied by systemic allergic manifestations; in such instances, the risk of administering antivenom must be weighed against the risk of withholding it |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Appropriate therapy for the treatment of anaphylaxis should be ready for immediate use |
| Media file 1: Lionfish (Pterois volitans) have long, slender spines with small venom glands, and they have the least potent sting of the Scorpaenidae family. (Courtesy Dee Scarr) | |
View Full Size Image | Media type: Photo |
| Media file 2: Scorpionfish (genus Scorpaena) have shorter, thicker spines with larger venom glands than lionfish do, and they have a more potent sting. (Courtesy Dee Scarr) | |
View Full Size Image | Media type: Photo |
| Media file 3: Stonefish (genus Synanceia) have short, stout spines with highly developed venom glands, and they have a potentially fatal sting. (Courtesy Paul S. Auerbach, MD) | |
View Full Size Image | Media type: Photo |
| Media file 4: Members of the genera Scorpaena, such as these scorpionfish, and Synanceia, such as the stonefish, usually are found well camouflaged on the sandy bottom of the sea or amongst rocks. Shoes or booties may provide some protection; however, it is best to avoid touching the sea bottom or to use a shuffling gait while wading. (Courtesy Dee Scarr) | |
View Full Size Image | Media type: Photo |
| Media file 5: Members of the genus Pterois, such as this lionfish, are usually free-swimming or hovering in small caves or crevices for protection. Provoking these fish by handling or cornering them may result in a painful envenomation. (Courtesy Dee Scarr) | |
![]() | View Full Size Image | Media type: Photo |
| Media file 6: In defense of the animals, envenomations and injury generally occur in response to a perceived threat, usually handling or stepping on the animals. (Photo by Scott A Gallagher, MD) | |
![]() | View Full Size Image | Media type: Photo |
| Media file 7: A 45-year-old diver was taking photographs in Australia at a depth of 60 feet. He suddenly noticed an excruciating pain in his left foot after resting his foot on a large stonefish. Photo courtesy John Williamson, MD and Surf Lifesaving Queensland. | |
![]() | View Full Size Image | Media type: Photo |
Lionfish and Stonefish excerpt
Article Last Updated: Jun 8, 2006